{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T18:32:47Z","timestamp":1779129167377,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Study Objective<\/jats:title><jats:p>The use of race in medicine can contribute to health inequity. Updated equations for estimated glomerular filtration rate (eGFR) without race have been published. Likewise, de\u2010indexation of eGFR to body surface area (BSA) has been recommended by regulatory guidance for drug dosing in renal impairment. Clinical data justifying these recommendations for drug dosing are sparse. We examined the gain or loss of precision in drug dosing with estimated creatinine clearance (eCLcr) and eGFR using serum creatinine (eGFRcr) with and without race and BSA indexation by evaluating the population pharmacokinetics of the aminoglycosides as a classic drug class to probe kidney function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Medical records from adult patients treated with gentamicin or tobramycin over a 13\u2010year period were queried. Population pharmacokinetic analyses were performed using a 1\u2010compartment base structural model. Models compared body size descriptors as covariates of the volume of distribution (V). Estimated creatinine clearance and eGFRcr using multiple contemporary equations with and without BSA indexation were tested as covariates of clearance (CL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Results<\/jats:title><jats:p>The final data set included 2968 patients treated with either gentamicin (20.2%) or tobramycin (79.8%). Patients self\u2010identified as Caucasian (82%), African\u2010American (10%), or other. The median [5th, 95th percentile] weight and BSA were 80.5 [49.4, 136]\u00a0kg and 1.94 [1.48, 2.56]\u00a0m<jats:sup>2<\/jats:sup>, respectively. Models of eCLcr and eGFRcr without indexation to BSA had a better model fit than eGFRcr indexed to BSA for aminoglycoside CL. The 2021 Chronic Kidney Disease Epidemiology collaboration (CKD\u2010EPI) eGFRcr equation (no race, no BSA indexation) provided a comparable model fit to the 2009 CKD\u2010EPI eGFRcr equation (with race, no BSA indexation) for aminoglycoside CL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Race is not a relevant covariate of aminoglycoside CL. The 2021 CKD\u2010EPI eGFR equation without race and BSA indexation is a better method for gentamicin and tobramycin CL estimation. Confirmation of these results for other drugs can support the harmonization of dosing by kidney function.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2746","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:15:45Z","timestamp":1668856545000},"page":"35-42","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Removing race and body surface area indexation for estimated kidney function based drug dosing: Aminoglycosides as justification of these principles"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-5034","authenticated-orcid":false,"given":"Manjunath P.","family":"Pai","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy University of Michigan  Ann Arbor Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirima","family":"Sitaruno","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences Prince of Songkla University  Songkhla Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abdelnabi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy University of Michigan  Ann Arbor Michigan USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04890421"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnma.2022.05.008"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2179"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000739"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.04.034"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114248"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.19152"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.03.008"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00377-6"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004234"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2016.01.023"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.02.393"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.11.012"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000330276"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-097X.2006.00718.x"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01108.x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd16.180579"},{"key":"e_1_2_9_22_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation Research.Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function \u2013Study Design Data Analysis and Impact on Dosing.2020."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02329-18"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1095-8312.2005.00458.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03891.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00174-11"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10050507"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00501-8"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajhb.20956"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000268955"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2004121100"},{"key":"e_1_2_9_33_1","first-page":"P25","volume-title":"Demographic Turning Points for the United States: Population Projections for 2020 to 2060","author":"Vespa JAD","year":"2018"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-021-03076-y"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270012439209"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1314"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2746","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:40:17Z","timestamp":1761043217000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/phar.2746"],"URL":"https:\/\/doi.org\/10.1002\/phar.2746","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"2022-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}